Allurion Technologies is a pioneering leader in the development of innovative, scalable and trusted weight loss experiences.
Allurion Technologies is dedicated to helping people realize their full potential with innovative, scalable and trusted experiences.
Allurion Technologies was founded in 2009 by Shantanu Gaur and Samuel Levy. The company is headquartered in Natick, Massachussetts, with offices in Paris and Dubai.
Allurion Technologies' flagship product, the Elipse Program, is a 360-degree weight loss experience featuring the Elipse Balloon, the world’s first and only swallowable, procedureless gastric balloon for weight loss.
Allurion Technologies launched commercial operations in 2016, and 10,000 consumers have already experienced the Elipse Program. More than 20,000 devices have already been distributed across 25 countries, with over half shipped this year alone.
Allurion Technologies is backed by Novalis LifeSciences, Romulus Capital, IDO Investments, ex-Covidien CEO Jose Almeida and others. The company raised $34M in a new round of funding on Jan 07, 2020. This brings Allurion's total funding to $90.5M to date.